Brentuximab vedotin
- PDF / 169,259 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 42 Downloads / 136 Views
1
S
Neutropenia: case report In a retrospective, observational study of 58 patients who received treatment with brentuximab vedotin between May 2013 and November 2015, one patient [age and sex not stated] was described, who developed grade 3/4 neutropenia during treatment with brentuximab vedotin initiated at 1.8 mg/kg every 3 weeks for up to a maximum of 16 cycles for relapsed/refractory Hodgkin lymphoma. Therefore, the dose of brentuximab vedotin was reduced to 1.2 mg/kg every 3 weeks [route, duration of treatment to reaction onset and outcome not stated] Author comment: "Only 1 patient (2%) required a reduction in the dose of [brentuximab vedotin] to 1.2mg/kg due to neutropenia (Grade 3/4)". Kral Z, et al. Treatment of relapsed/refractory Hodgkin lymphoma: Real-world data from the Czech Republic and Slovakia. Journal of Cancer 10: 5041-5048, No. 21, 28 Aug 2019. Available from: URL: http://doi.org/10.7150/jca.29308 - Czech 803433393 Republic
0114-9954/19/1779-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved
Reactions 16 Nov 2019 No. 1779
Data Loading...
